Redefining What's Possible: The Future of Myeloma Therapy in 2027 | Jeff Matous, MD

Dr. Jeff Matous looks ahead at where multiple myeloma treatment is headed, from how far care has come since the era of VAD chemotherapy and high-dose dexamethasone, to the new drug classes arriving in 2026 and 2027. He covers CELMoDs (iberdomide and mezigdomide), a new generation of cereblon-targeting drugs related to Revlimid and Pomalyst, the antibody-drug conjugate belantamab mafodotin and the DREAMM-7 trial data behind its approval, and early results from in vivo CAR-T, a next-generation approach that makes CAR-T cells inside the patient's own body instead of in a lab, eliminating the need for apheresis, weeks of manufacturing, and pre-treatment chemotherapy. He closes with why clinical trials remain the single best treatment option in myeloma, and why basic research funding is currently under threat.